1stOncology™: Cancer Intelligence Service – Page 74 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

QIAGEN Sets 2026 Priorities to Drive Growth Across Five Pillars Toward Achieving 2028 Goals for Solid Profitable Growth

On January 12, 2026 QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) reported its 2026 priorities across its five growth pillars focused on advancing product commercialization, regulatory milestones and automation system innovations to support its goal for $2 billion of combined annual pillar sales in 2028.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Following strong operational execution in 2025, QIAGEN enters 2026 with plans for new product launches and submissions among its pillars designed to expand addressable markets, increase its installed base of automation systems and strengthen recurring consumables and software revenues across the continuum from life sciences to diagnostics customers.

The five pillars – Sample technologies, QIAstat-Dx syndromic testing, QIAcuity digital PCR, QIAGEN Digital Insights (QDI) bioinformatics and QuantiFERON for latent tuberculosis testing – represent areas where QIAGEN has established leadership and scaling differentiated platforms with growth potential.

"We delivered on key targets in 2025 and enter 2026 with strong momentum," said Thierry Bernard, CEO of QIAGEN. "Our investments we are making in automation, menu expansion and AI, together with targeted and differentiated acquisitions, are designed to accelerate growth, advancing in high-value areas of life sciences and diagnostics and sharpening our competitive edge as we move toward achieving our 2028 ambitions."

Sample technologies: Adding Parse single-cell analysis and launching new systems

In December 2025, QIAGEN completed the acquisition of Parse Biosciences, expanding its Sample technologies portfolio into single-cell analysis. Parse’s instrument-free Evercode chemistry is used by more than 3,000 customers and supports large-scale single-cell studies, strengthening QIAGEN’s exposure to a fast-growing research segment.

Parse is expected to contribute approximately $40 million in sales in 2026, with opportunities to scale through QIAGEN’s global commercial infrastructure. Recent launches such as Evercode Whole Blood Fixation, a new kit that enables immediate fixation of whole blood directly at the point of collection, are set to extend Parse’s reach into translational and clinical research workflows.

QIAGEN is also advancing the launches of three new sample preparation systems in 2026 to address demand for automation and throughput in applications, in particular liquid biopsy, minimal residual disease testing and microbiome research. These new systems, which will be exhibited at the SLAS Show in February 2026, are designed to expand the installed base of instruments and drive consumables pull-through over time:

QIAsymphony Connect: Controlled placements began in late 2025, with IVDR commercialization targeted for mid-2026. This new generation of QIAsymphony enables faster processing, improved connectivity and workflow standardization, especially with up to 50% higher throughput for certain liquid biopsy applications.
QIAsprint Connect: First purchase orders were received in 2025 ahead of launch in February 2026 of this new system that marks QIAGEN’s entry into high-throughput sample processing. It enables preparation of up to 192 samples per run while reducing plastic consumption.
QIAmini: On track for launch in Fall 2026, this compact system offers walkaway automation for lower-throughput labs seeking affordable, user-friendly solutions.
QIAstat-Dx: Expanding test menu and building installed base

QIAGEN submitted in December 2025 its first blood culture identification (BCID) panels for regulatory clearance in the U.S. and CE-IVDR registration, extending the QIAstat-Dx menu into bloodstream infections and sepsis-related applications.

At year-end 2025, cumulative QIAstat-Dx placements exceeded 5,200 instruments worldwide, providing a solid foundation for future growth. The BCID submissions build on six U.S.-cleared panels and three CE-IVDR panels already commercialized internationally. In the U.S., gastrointestinal panels have also been submitted for use on QIAstat-Dx Rise, the higher-throughput platform designed for larger laboratories with capacity of up to 160 tests per day.

The development pipeline includes panels for complicated urinary tract infections (cUTI) and pneumonia, as well as additional panels for companion diagnostics developed with pharmaceutical partners.

QIAcuity digital PCR: Scaling pharma adoption and improving workflow automation

QIAGEN plans to expand its QIAcuity digital PCR portfolio in 2026 with the launch of thousands of new gene expression assays, further strengthening adoption in pharmaceutical and biopharma applications.

To support higher-throughput and standardized workflows, QIAGEN and Hamilton have co-developed an automated nanoplate handling solution on the Microlab STAR platform, enabling walkaway automation from pipetting through plate sealing prior to QIAcuity loading. This integration supports reproducibility across sites, an important requirement for regulated and GMP-compliant environments.

QIAcuity adoption continues to grow across academia, biopharma and clinical research, with over 3,200 cumulative placements at the end of 2025. New assay offerings, including lentivirus detection and host-cell DNA sizing kits planned for 2026, are designed to expand use in Cell and Gene Therapy manufacturing and quality control.

QDI: Advancing AI-enabled bioinformatics and expanding single-cell applications

QIAGEN Digital Insights (QDI) plans for multiple new product advancements in 2026 as part of its roadmap to introduce at least 14 AI-enabled software solutions by 2028.

Key priorities for 2026 include the rollout of new AI capabilities for pharmaceutical R&D, multilingual automation for clinical reporting and agentic AI decision support for novel target identification. These AI offerings aim to better identify insights from high-quality curated genomics knowledge and accelerate precision in clinical decision-making in areas such as oncology and hereditary disease diagnostics.

QDI is also gaining momentum from the integration and expansion of the Franklin platform, which was acquired with Genoox in 2025. Franklin now combines trusted content from QIAGEN’s clinical interpretation portfolio with intuitive AI-supported workflows to guide genetic analysis and reporting across hereditary and oncology applications.

QDI is also planning to integrate single-cell datasets generated through Parse Biosciences, enabling development of predictive modeling and target discovery tools for pharmaceutical partners in areas including oncology, neurology and immunology.

QuantiFERON: Accelerating workflow automation and AI-related investments

QIAGEN is developing a fifth generation of its QuantiFERON test, with updates planned during 2026 as part of its commitment to leadership in tuberculosis diagnostics. The new version will build on the proven performance of earlier generations while introducing improvements to support laboratories facing increasing testing demands.

In parallel, a new generation of chemistry for partner Diasorin’s LIAISON QuantiFERON-TB Gold Plus II assay is planned for U.S. launch in early 2026, following its introduction in Europe in 2025. The updated assay enables laboratories to test up to 75% more patients per hour and deliver results 25% faster than the previous version on the automated LIAISON platforms. QIAGEN is continuously working on workflow solutions to help customers handle increasing testing demands.

Latent TB infection affects an estimated one in four people globally, with up to 10% at risk of progressing to active disease if left untreated. To support assessment of progression risk, QIAGEN is investigating the use of AI to facilitate clinical decision making to guide preventive treatment and improve patient care. About 60% of the global latent TB testing market still relies on the 120-year-old skin test, offering significant opportunities for ongoing conversion to modern blood-based diagnostics like QuantiFERON.

(Press release, Qiagen, JAN 12, 2026, View Source [SID1234661967])

PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference

On January 12, 2026 PTC Therapeutics, Inc. (NASDAQ: PTCT) reported an update on the Company’s progress and its outlook for 2026. Matthew B. Klein, M.D., Chief Executive Officer of PTC, will discuss these updates at the Company’s presentation at the J.P. Morgan 2026 Healthcare Conference on Monday, January 12, 2026, at 9:00 a.m. PST / 12:00 p.m. EST.

"2025 was a highly successful year for PTC, highlighted by the initial regulatory approvals of Sephience and strong start to the global launch," Dr. Klein said. "In 2026, we look forward to continuing the Sephience launch momentum, advancing our innovative earlier-stage programs and moving the company towards becoming cash flow breakeven."

Key Corporate Highlights

Unaudited 2025 product and royalty revenue of approximately $823.4 million, exceeding guidance, and unaudited 2025 product revenue of approximately $587.8 million
Unaudited Sephience Q4 2025 net revenue of approximately $92.5 million, including $81.6 million in the US and $10.9 million ex-US
Unaudited Sephience total net revenue of approximately $112.1 million in 2025 since launch
1,134 patient start forms received in the US as of December 31, 2025
946 total patients on commercial therapy worldwide as of December 31, 2025
Additional Sephience launches expected in 2026, including in Japan, Brazil and other geographies
In December 2025, PTC sold the remainder of its Evrysdi (risdiplam) royalty to Royalty Pharma for $240 million upfront and up to $60 million in sales-based milestones; PTC maintains the right to receive a $150 million milestone based on single-year Evrysdi sales of $2.5 billion by Roche
Cash, cash equivalents, and marketable securities of approximately $1.94 billion as of December 31, 2025
End-of-Phase 2 meeting with FDA held in Q4 2025 to discuss the votoplam Huntington’s disease (HD) program:
Alignment reached on design of global Phase 3 trial, planned to initiate in H1 2026
FDA confirmed openness to potential Accelerated Approval pathway given significant unmet need
Type C meeting with FDA held in December 2025 to discuss vatiquinone Friedreich’s ataxia program; FDA requested additional information from MOVE-FA Phase 3 trial prior to providing guidance on next steps
Translarna (ataluren) NDA remains under FDA review
Unaudited 2025 Financial Results

Total unaudited product and royalty revenue for full-year 2025 was approximately $823.4 million
Total unaudited product revenue for full-year 2025 was approximately $587.8 million
Sephience unaudited total net revenue for 2025 was approximately $112.1 million
DMD franchise unaudited revenue for full-year 2025 was approximately $381.8 million, including unaudited product revenue for Translarna of approximately $235.5 million and for Emflaza (deflazacort) of approximately $146.3 million
PTC expects to report approximately $235.7 million of full-year 2025 royalty revenue associated with Evrysdi
PTC is finalizing its financial results for the 2025 fiscal year. The above information is based on preliminary unaudited information and management estimates for the full year 2025, subject to the completion of PTC’s financial closing procedures. Evrysdi royalty revenue estimates are based on internal estimates and pending accounting treatment of Evrysdi royalty following the December 2025 transaction.

2026 Financial Guidance
For the full year 2026, PTC anticipates:

Total product revenue of $700 to $800 million, excluding Evrysdi royalty revenue and collaboration revenue
GAAP R&D and SG&A expense of $775 to $815 million
Non-GAAP R&D and SG&A expense of $680 to $720 million, excluding estimated non-cash, stock-based compensation expense of $95 million

(Press release, PTC Therapeutics, JAN 12, 2026, View Source [SID1234661966])

Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones

On January 12, 2026 Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, reported recent updates and anticipated 2026 milestones.

"On the heels of a remarkable year marked by meaningful progress across the entirety of our pipeline, we are entering 2026 with unwavering resolve to continue to execute on our mission to deliver transformative therapies to patients with cancer and rare diseases," said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics. "For our non-muscle invasive bladder cancer (NMIBC) program, our growing body of clinical data continue to support that TARA-002 could serve as a differentiated, easy to administer treatment option across the NMIBC treatment landscape. Following our recent ADVANCED-2 update in which TARA-002 demonstrated meaningful and durable activity in BCG-Naïve NMIBC patients, we look forward to providing an interim update on the registrational BCG-Unresponsive trial later this quarter."

Mr. Shefferman added, "We have also made important progress in our rare disease programs. Following positive results from the ongoing Phase 2 STARBORN-1 trial of TARA-002 in lymphatic malformations (LMs), we were pleased that the FDA granted this program both Breakthrough Therapy and Fast Track designations and we expect to provide a regulatory update defining the path to registration in the first half of this year. Additionally, we were pleased to announce that the first patient has been dosed in our registrational THRIVE-3 trial of IV Choline Chloride in patients on long-term parenteral support (PS) and expect to provide an interim analysis in the second half of 2026. We believe we are well positioned for continued success with several key milestones anticipated in the year ahead."

Recent Company Updates and Planned 2026 Milestones

TARA-002 in NMIBC

Protara remains on track to report in the first quarter of 2026 interim results in approximately 25 six-month evaluable patients from its ongoing Phase 2 open-label ADVANCED-2 trial in NMIBC patients with carcinoma in situ or CIS (± Ta/T1) who are Bacillus Calmette-Guérin (BCG)-Unresponsive.

In December 2025, the Company reported positive interim results from its ongoing Phase 2 open-label ADVANCED-2 trial in NMIBC patients with CIS (± Ta/T1) who are BCG-Naïve at the 26th Annual Meeting of the Society of Urologic Oncology (SUO) in which TARA-002 demonstrated meaningful response rates at six and 12 months and a favorable safety and tolerability profile. Based on feedback from the U.S. Food and Drug Administration (FDA), the Company plans to commence a registrational trial of TARA-002 compared to intravesical chemotherapy in BCG-naïve patients in the second half of 2026.

Protara continues to evaluate subcutaneous dosing through priming and maintenance combined with intravesical dosing, as well as exploring combination treatments with TARA-002 in NMIBC patients with CIS.

TARA-002 in LMs

Protara recently announced that the FDA granted TARA-002 both Fast Track and Breakthrough Therapy designations for the treatment of pediatric patients with macrocystic and mixed cystic LMs. TARA-002 previously was granted Rare Pediatric Disease designation for the treatment of LMs.

The Company plans to share a regulatory update on the path forward for registration for TARA-002 in LMs in the first half of 2026.

TARA-002 Manufacturing Update

Protara recently announced that TARA-002 has been selected to participate in this year’s FDA Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) Program. The FDA created the CDRP Program to facilitate CMC development for therapies with compressed clinical development timeframes based on the anticipated clinical benefits of earlier patient access to the therapy. The initiative is designed to promote earlier and more structured engagement between sponsors and FDA on CMC development strategies, and since its inception, has led to increased collaboration with the FDA so sponsors can confidently scale up manufacturing capacity while clinical development is ongoing.

IV Choline Chloride for Patients on PS

The Company recently announced that the first patient has been dosed in THRIVE-3 (NCT06910943), a seamless Phase 2b/3 trial designed to assess the efficacy and safety of low and high dose IV Choline Chloride in adolescent and adult patients receiving long-term PS when oral or enteral nutrition is not possible, insufficient, or contraindicated. Following an 8-week Phase 2b open-label, dose-confirmation trial in 24 patients, approximately 105 additional patients will be enrolled in a 24-week Phase 3 double-blinded, randomized, placebo-controlled trial. The primary endpoint of the trial is the change in plasma choline concentration from baseline compared to placebo. The Company expects to report interim results in the second half of 2026.

Corporate Update

In December 2025, the Company announced that it closed an underwritten public equity offering of approximately $86 million before deducting underwriting discounts and commissions and offering expenses payable by Protara. The proceeds from the offering are expected to extend the Company’s cash runway into 2028.

(Press release, Protara Therapeutics, JAN 12, 2026, View Source [SID1234661965])

ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones

On January 12, 2026 ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, reported operational highlights for 2025 and anticipated upcoming milestones.

"2025 was a transformative and highly productive year for ORIC, marked by meaningful progress across our pipeline, including data that further strengthened our conviction in the potential best-in-class profiles of rinzimetostat in prostate cancer and enozertinib in lung cancer," said Jacob M. Chacko, M.D., president and chief executive officer. "We also bolstered our leadership team and substantially extended our cash runway into 2H 2028 in anticipation of these programs advancing towards registrational studies and, ultimately, commercialization."

2025 Key Accomplishments

Rinzimetostat: a potent and selective allosteric inhibitor of PRC2

Completed Phase 1b dose exploration in prostate cancer and selected provisional recommended Phase 2 doses (RP2Ds) of rinzimetostat to be tested in combination with the approved doses of darolutamide and apalutamide in dose optimization.
Reported potential best-in-class efficacy and safety dose exploration data in combination with darolutamide and apalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC). Data demonstrated:
PSA responses and ctDNA reductions across all rinzimetostat dose levels and at comparable rates in combination with apalutamide or with darolutamide.
Broad and deep PSA responses that compare favorably to competitor PRC2 inhibitors, with 55% of patients (11/20) achieving a PSA50 response (confirmed in 40%), and 20% of patients (4/20) achieving a PSA90 response (all confirmed).
Rapid and deep ctDNA responses across a breadth of AR mutations and other gene alterations, with 76% (13/17) achieving > 50% ctDNA reduction, and 59% (10/17) achieving ctDNA clearance, which is greater than clearance rates observed in precedent trials with standard of care agents in comparable mCRPC patient populations.
Both combination regimens demonstrated a clearly differentiated safety profile compatible with long-term dosing, with the vast majority of treatment-related adverse events (TRAEs) Grade 1 or 2 in severity and consistent with PRC2 and AR inhibition.
Presented preclinical data at the EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium on Molecular Targets and Cancer Therapeutics demonstrating potential utility of rinzimetostat combined with AR inhibition in castration-sensitive prostate cancer and combined with KRAS inhibition in KRAS G12C-mutant NSCLC and colorectal cancer models.

Enozertinib: a brain-penetrant inhibitor that selectively targets EGFR exon 20 and EGFR PACC mutations

Reported potential best-in-class efficacy and safety data from a Phase 1b trial of enozertinib at the ESMO (Free ESMO Whitepaper) Asia Congress 2025 in NSCLC patients with EGFR exon 20 and EGFR PACC mutations. Data demonstrated:
Systemic activity in 2L EGFR exon 20 and pretreated EGFR PACC exceeding competitor benchmarks.
Highly competitive preliminary 1L systemic activity, with 67% ORR in EGFR exon 20 and 80% ORR in EGFR PACC.
Convincing 1L CNS activity, with 100% intracranial ORR in EGFR exon 20 and 100% intracranial ORR in EGFR PACC in patients with measurable CNS disease, including in patients with active brain metastases.
Competitive safety profile, with no significant off-target toxicity, resulting in low rate of treatment discontinuations.
Announced a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate enozertinib in combination with amivantamab and hyaluronidase-lpuj subcutaneous injection (SC amivantamab) for the 1L treatment of NSCLC patients with EGFR exon 20 mutations.
Announced publication in Cancer Research of preclinical data demonstrating enozertinib’s exquisite selectivity, strong potency, brain-penetrance, and anti-tumor activity across a broad range of EGFR atypical mutant models, including intracranial lung cancer xenografts.

Corporate Highlights:

Announced the appointment of Kevin Brodbeck, PhD, to the newly established role of Chief Technical Officer (CTO).
Strengthened cash position and extended runway with $244 million in gross proceeds raised from new and existing top-tier healthcare specialist funds via private placement in May 2025 and under the ATM (at-the-market) program throughout 2025.

Anticipated Program Milestones:

ORIC anticipates the following upcoming milestones:

Rinzimetostat in mCRPC:
1Q 2026: Combination dose optimization data with AR inhibitor
1H 2026: Initiate first global Phase 3 registrational trial in mCRPC
2H 2026: Program update
Enozertinib in NSCLC:
2H 2026: 1L EGFR exon 20 monotherapy data and combination data with SC amivantamab
2H 2026: 1L EGFR PACC monotherapy data

Financial Guidance
As of September 30, 2025, cash, cash equivalents and investments totaled $413.0 million, which the company expects will be sufficient to fund its operating plan into 2H 2028, beyond several potential value inflection points, including anticipated primary endpoint readout from first Phase 3 trial of rinzimetostat.

Presentation and Webcast
Jacob M. Chacko, M.D., president and chief executive officer, will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2025, at 9:45 a.m. PT. A live webcast will be available through the investor section of the company’s website at www.oricpharma.com. A replay of the webcast will be available for 90 days following the event.

(Press release, ORIC Pharmaceuticals, JAN 12, 2026, View Source [SID1234661964])

Corporate overview

On January 12, 2026 Olema Oncology presented its corporate presentation.

(Presentation, Olema Oncology, JAN 12, 2026, View Source [SID1234661963])